MMRF

Reverb Therapeutics Debuts Its Amplifier™ Platform for Redirecting Endogenous Cytokines 

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Professional Services, Health, Philanthropy, General Health, Pharmaceutical, Oncology, Other Philanthropy, Research, Science, Finance, Amplifier, Multiple myeloma, Cytokine, School, Preamplifier, Alexion, AstraZeneca, Therapy, Toxicity, University of British Columbia, Boehringer Ingelheim, Risk, Flagship Pioneering, CSO, MMRF, Patient, Systems biology, Element, SAB, Amplitude, University, Antibody, Zymeworks, Cancer, Neoplasm, Harvard University, Biomedical engineering, Cell, Immunoglobulin G, Vaccine, Management, Pfizer, Reverberation

Reverb Therapeutics, a leader in the emerging paradigm of redirecting endogenous cytokines as treatments for life-threatening diseases, debuts with seed financing led by founding investor Amplitude Ventures and participation from the Multiple Myeloma Research Foundation’s venture philanthropy arm, the Myeloma Investment Fund .

Key Points: 
  • Reverb Therapeutics, a leader in the emerging paradigm of redirecting endogenous cytokines as treatments for life-threatening diseases, debuts with seed financing led by founding investor Amplitude Ventures and participation from the Multiple Myeloma Research Foundation’s venture philanthropy arm, the Myeloma Investment Fund .
  • Reverb Therapeutics is advancing its novel antibody-based AmplifierTM platform to treat a broad range of diseases with endogenous cytokines that naturally occur within the body.
  • Instead of using heavily engineered exogenous cytokines to treat disease—which have consistently presented challenges such as systemic toxicity, immunogenicity and challenging production requirements—Reverb’s antibodies redirect endogenous, natural cytokines to cells of interest.
  • “We are keenly aware of the clinical obstacles to more widespread use of exogenous cytokines to treat patients,” said David de Graaf, Ph.D., Co-founder and CEO of Reverb Therapeutics.

The Multiple Myeloma Research Foundation Announces $21M Grant Program to Support Multicenter Translational Research Networks

Retrieved on: 
Thursday, November 2, 2023
Research, General Health, Philanthropy, Oncology, Genetics, Fund Raising, Foundation, Science, Biotechnology, Other Philanthropy, Other Science, Health, Multiple myeloma, Attention, Multiple Myeloma Research Foundation, MMRF, Doctor of Philosophy, Patient, MAC, HR, Pharmaceutical industry

The Multiple Myeloma Research Foundation (MMRF) announced today the recipients of three $7 million MMRF Myeloma Accelerator Challenge (MAC) Program Grants totaling $21 million.

Key Points: 
  • The Multiple Myeloma Research Foundation (MMRF) announced today the recipients of three $7 million MMRF Myeloma Accelerator Challenge (MAC) Program Grants totaling $21 million.
  • “These MAC Grants are a critical new part of this investment, and we are excited that the programs selected will bring together multiple centers to work in highly collaborative networks.
  • The first is optimizing first-line therapy for high-risk newly diagnosed multiple myeloma because high-risk patients often relapse early and show inferior survival compared to standard-risk patients.
  • The next is improving identification of high-risk smoldering multiple myeloma (HR SMM); smoldering multiple myeloma is an early, asymptomatic stage that can progress to active multiple myeloma.

Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation

Retrieved on: 
Thursday, November 2, 2023
Multiple myeloma, CAR, Icahn Genomics Institute, Black, Associate, Washington University in St. Louis, Therapy, CRISPR, Genetics, Bone marrow, Icahn School of Medicine at Mount Sinai, Early Prostate Cancer (clinical programme), Translational research, Doctor of Philosophy, Multiple Myeloma Research Foundation, Research, MAC, Stanford University Medical Center, Mount Sinai Health System, University of California, San Francisco, Genomics, Growth, Disease, MMRF, Immunotherapy, University, Gene, Hackensack University Medical Center, San Francisco, Cancer, Patient, Marc, Pharmaceutical industry, Vaccine, MD

NEW YORK, Nov. 2, 2023 /PRNewswire-PRWeb/ -- The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.

Key Points: 
  • Multiple myeloma is a blood cancer that develops in the bone marrow and can spread throughout the body.
  • In 2023, more than 35,000 Americans are projected to be diagnosed with multiple myeloma and approximately 12,000 will lose their lives.
  • Researchers hope to uncover the full landscape of genomic, proteomic and immune differences between high- and standard-risk multiple myeloma patients.
  • "The three exciting programs we selected each have potential to answer fundamental questions about multiple myeloma and help advance rational treatments for this cancer."

The Multiple Myeloma Research Foundation (MMRF) Names Stephanie Oestreich, Ph.D., MPA, as Managing Director of the Myeloma Investment Fund (MIF)

Retrieved on: 
Thursday, October 5, 2023
Biotechnology, Health, Other Health, Pharmaceutical, Other Philanthropy, Philanthropy, Oncology, Other Science, Research, General Health, Fund Raising, Health Technology, Foundation, Science, RA, John F. Kennedy High School, Faculty, Business, Drug development, ARCH Venture Partners, Multiple myeloma, Multiple Myeloma Research Foundation, Harvard University, Novartis, American Business Council Nigeria, Arm, Galecto Biotech, Therapy, W20, MMRF, MIT, G20, MPA, Growth, CART, Evotec, Business development, Commercial, Patient, Management, Bruker

The Multiple Myeloma Research Foundation (MMRF) has announced the appointment of Stephanie Oestreich, Ph.D., MPA, as Managing Director of its venture philanthropy subsidiary, the Myeloma Investment Fund (MIF).

Key Points: 
  • The Multiple Myeloma Research Foundation (MMRF) has announced the appointment of Stephanie Oestreich, Ph.D., MPA, as Managing Director of its venture philanthropy subsidiary, the Myeloma Investment Fund (MIF).
  • In this role, Dr. Oestreich will lead the overall execution of the MIF’s investment strategy and serve as a member of the MMRF executive leadership team.
  • “We are thrilled to have Dr. Oestreich join our team as Managing Director of the MIF,” said Michael Andreini, President and CEO, the MMRF.
  • “The MIF invests in the most promising companies that are developing innovative clinical assets and technologies that could be transformative for myeloma patients.

MMRF Research Programs Expand Understanding of the Biology of Multiple Myeloma and Patient-Reported Outcomes in New Data Featured at the 20th IMS Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Biotechnology, Health, Philanthropy, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Foundation, Science, Abstract, Patient-reported outcome, Multiple myeloma, PRO, Multiple Myeloma Research Foundation, Publication, Data, Patient, IMS, Biology, Disease, MMRF, Pharmaceutical industry

The Multiple Myeloma Research Foundation (MMRF) today announced that findings from three studies based on analyses of its CoMMpass℠ and CureCloud℠datasets will be featured in an oral abstract and poster presentations at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece, September 27-30, 2023.

Key Points: 
  • The Multiple Myeloma Research Foundation (MMRF) today announced that findings from three studies based on analyses of its CoMMpass℠ and CureCloud℠datasets will be featured in an oral abstract and poster presentations at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece, September 27-30, 2023.
  • Topics include:
    A real-world longitudinal investigation of patient treatments and outcomes, including Patient Reported Outcome (PRO) surveys from the MMRF CureCloud Research Initiative
    Additionally, data from the CoMMpass Study are cited in 24 posters and four education sessions, demonstrating its enduring value in driving new advancements across multiple myeloma research.
  • To develop a more comprehensive picture of myeloma disease biology, the MMRF is expanding the CoMMpass dataset with immune data from its Immune Atlas research program.
  • The MMRF makes the datasets from CoMMpass, Immune Atlas, and CureCloud available to researchers, facilitating the development of optimal treatments for all myeloma patients.

Moving Mountains for Multiple Myeloma® Program to Trek Through Alaska, July 23-29

Retrieved on: 
Thursday, July 20, 2023
Fund Raising, Foundation, Philanthropy, GSK, Multiple Myeloma Research Foundation, Friends, Multiple myeloma, Bone marrow, Research, MGUS, Patient, Moving Mountains, Nursing, B cell, Diagnosis, Caregiver, Disease, MMRF, Pharmaceutical industry

The MM4MM Alaska trek is a Multiple Myeloma Research Foundation (MMRF) initiative sponsored by GSK.

Key Points: 
  • The MM4MM Alaska trek is a Multiple Myeloma Research Foundation (MMRF) initiative sponsored by GSK.
  • Since MM4MM began with its first trek in 2016, the program has raised over $3 million for multiple myeloma research.
  • The upcoming Alaska trek will include an extraordinary group of multiple myeloma patients, caregivers, friends and family members, nurses, and team members from the organizing partners.
  • More than 50 years ago, her father passed away from multiple myeloma, and just two years ago, her husband, Ed, was diagnosed with smoldering multiple myeloma.

Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma

Retrieved on: 
Tuesday, May 16, 2023
Research, Philanthropy, Biotechnology, General Health, Pharmaceutical, Health, Foundation, Science, Oncology, Other Science, Multiple Myeloma Research Foundation, Partnership, Multiple myeloma, PVR, Patient, Investment, Escape Room, Therapy, MMRF, Pharmaceutical industry, Nectin

Nectin Therapeutics , a biotechnology company developing novel targeted immunotherapies to address tumor immune resistance, and the Myeloma Investment Fund (MIF) , the Multiple Myeloma Research Foundation's (MMRF) venture philanthropy subsidiary, today announced that the MIF has invested in Nectin Therapeutics to explore the potential of NTX1088, Nectin’s first-in-class lead immunotherapy drug candidate, for the treatment of multiple myeloma.

Key Points: 
  • Nectin Therapeutics , a biotechnology company developing novel targeted immunotherapies to address tumor immune resistance, and the Myeloma Investment Fund (MIF) , the Multiple Myeloma Research Foundation's (MMRF) venture philanthropy subsidiary, today announced that the MIF has invested in Nectin Therapeutics to explore the potential of NTX1088, Nectin’s first-in-class lead immunotherapy drug candidate, for the treatment of multiple myeloma.
  • "We look forward to our partnership with Nectin Therapeutics to evaluate NTX1088 as a potential therapy for multiple myeloma,” said Michael Andreini, President and Chief Executive Officer of the Multiple Myeloma Research Foundation.
  • “The MIF is committed to identifying and accelerating the most innovative treatment approaches for myeloma patients.
  • We are pleased to support this first-in-class antibody targeting PVR based on the potential to overcome immune evasion and enhance the immune system’s response against myeloma.”
    “We are delighted to join forces with the Myeloma Investment Fund, allowing us to collaborate and explore the potential of our lead candidate, NTX1088, in the treatment of multiple myeloma," said Fabian Tenenbaum, Chief Executive Officer of Nectin.

Demonstration of Accurate Screening of Gene Dependency in Multiple Myeloma from Aitia's Gemini Digital Twins to be Presented at 2023 AACR Annual Meeting

Retrieved on: 
Tuesday, April 11, 2023
Survivor, AACR, Multiple myeloma, Medicine, Multiple Myeloma Research Foundation, American Association for Cancer Research, Patient, MM, Digital twin, MMRF, Medical imaging, Causality (physics)

SOMERVILLE, Mass., April 11, 2023 /PRNewswire/ -- Aitia, the leader in the application of causal AI and "Digital Twins" to discover and develop new drugs, announced today that data from its Multiple Myeloma Digital Twin model will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held from April 14-19 in Orlando, Florida.

Key Points: 
  • SOMERVILLE, Mass., April 11, 2023 /PRNewswire/ -- Aitia, the leader in the application of causal AI and "Digital Twins" to discover and develop new drugs, announced today that data from its Multiple Myeloma Digital Twin model will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held from April 14-19 in Orlando, Florida.
  • The presentation will discuss Aitia's in-silico multiple myeloma (MM) patient causal model of overall survival (OS) based on transcriptomic expression, clinical, and genomic alteration data from the Multiple Myeloma Research Foundation (MMRF) CoMMpass dataset (IA19).
  • Details of the abstract and poster presentation are as follow:
    The 2023 AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.

MMRF Programs Drive Advances in Cancer Research at 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Other Health, Research, General Health, Pharmaceutical, Philanthropy, Oncology, Foundation, Clinical Trials, Science, Biotechnology, Other Science, Health, Melanoma, Multiple Myeloma Research Foundation, Multiple myeloma, Daratumumab, Arm, Immune system, MMRF, ORR, IPD, Immunotherapy, Diagnosis, CD38, Society, Biomarker, Patient, 2021 Essex County Council election, Cancer, MAPK, Research, Precision medicine, Neoplasm, FDA, Risk assessment, MMRC, Dexamethasone, Genomics, Bone marrow, Clinical trial, Tissue, ASH, Pharmaceutical industry, Vaccine

The insights gained by these two innovative studies demonstrate the importance of generating and sharing a wide array of data.

Key Points: 
  • The insights gained by these two innovative studies demonstrate the importance of generating and sharing a wide array of data.
  • The MMRC focuses primarily on trials like MyDRUG that require the collaboration of many sites, given their specificity and scale.
  • The MMRF CoMMpass Study is an ongoing longitudinal study of patients with newly diagnosed active multiple myeloma.
  • The MMRF has raised more than $500 million and directs nearly 90% of the total funds to research and related programs.

Patient Registry Software Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Friday, December 2, 2022
Multiple Myeloma Research Foundation, Premier, Inc., EHR, Precision medicine, Biotechnology, MMRF, IQVIA, McKesson Corporation, COVID-19, Economy, Registry, MRO, Azerbaijan and Organization for Economic Co-operation, Multiple myeloma, Health, Population Health Management, OECD, Emergency, Growth, OpenText, Software, Patient, Disease, Direct, Hospital, Research report, DTP, Organization, Acquisition, Diagnosis, Database, EMR, Health information exchange, Pharmaceutical industry, Medical imaging, Asset management, Healthcare, Medical device, Development

The patient registry software market is expected to grow to $2.96 billion in 2026 at a CAGR of 13.2%.

Key Points: 
  • The patient registry software market is expected to grow to $2.96 billion in 2026 at a CAGR of 13.2%.
  • An EMR can help with billing, inter-practice referrals, appointment scheduling, and medication refills.The patient registry software functionality is included as an add-on in EMR and EHR products, thereby promoting the patient registry software market.
  • Product innovations are the key trends gaining popularity in the patient registry software market.Major companies operating in the patient registry software sector are focused on developing new product innovations to strengthen their position in the market.
  • The patient registry software market research report is one of a series of new reports that provides patient registry software market statistics, including patient registry software industry global market size, regional shares, competitors with patient registry software market share, detailed patient registry software market segments, market trends and opportunities, and any further data you may need to thrive in the patient registry software industry.